Related references
Note: Only part of the references are listed.Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
Benoist Chibaudel et al.
CANCER MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
T. C. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy
Elena De Mattia et al.
DRUG RESISTANCE UPDATES (2015)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients
Sylvia Chen et al.
PHARMACOGENETICS AND GENOMICS (2015)
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients
S. Chen et al.
PHARMACOGENOMICS JOURNAL (2015)
Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting
Chien-Yu Lu et al.
TRANSLATIONAL ONCOLOGY (2015)
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
Lei Cheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Irinotecan Pharmacogenetics: A Finished Puzzle?
Mitch A. Phelps et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice
Dilek Iusuf et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
X. Liu et al.
PHARMACOGENOMICS JOURNAL (2014)
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A. C. Roy et al.
ANNALS OF ONCOLOGY (2013)
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A. H. Ko et al.
BRITISH JOURNAL OF CANCER (2013)
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
Lucia Cortejoso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
Xun Cai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Uwe Pelzer et al.
EUROPEAN JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
B. Glimelius et al.
PHARMACOGENOMICS JOURNAL (2011)
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
Masahide Onoue et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients
Srinivasa Rao Jada et al.
CANCER SCIENCE (2007)
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:: roles of UGT1A1*6 and*28
Hironobu Minami et al.
PHARMACOGENETICS AND GENOMICS (2007)
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
Kazuhiro Araki et al.
CANCER SCIENCE (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability
FA de Jong et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
